These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37788223)

  • 21. Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
    Yang JJ; Wen W; Zahed H; Zheng W; Lan Q; Abe SK; Rahman MS; Islam MR; Saito E; Gupta PC; Tamakoshi A; Koh WP; Gao YT; Sakata R; Tsuji I; Malekzadeh R; Sugawara Y; Kim J; Ito H; Nagata C; You SL; Park SK; Yuan JM; Shin MH; Kweon SS; Yi SW; Pednekar MS; Kimura T; Cai H; Lu Y; Etemadi A; Kanemura S; Wada K; Chen CJ; Shin A; Wang R; Ahn YO; Shin MH; Ohrr H; Sheikh M; Blechter B; Ahsan H; Boffetta P; Chia KS; Matsuo K; Qiao YL; Rothman N; Inoue M; Kang D; Robbins HA; Shu XO
    J Thorac Oncol; 2024 Mar; 19(3):451-464. PubMed ID: 37944700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
    Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
    Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data.
    Gould MK; Huang BZ; Tammemagi MC; Kinar Y; Shiff R
    Am J Respir Crit Care Med; 2021 Aug; 204(4):445-453. PubMed ID: 33823116
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung cancer risk by years since quitting in 30+ pack year smokers.
    Pinsky PF; Zhu CS; Kramer BS
    J Med Screen; 2015 Sep; 22(3):151-7. PubMed ID: 25926339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Pinsky PF; Berg CD
    J Med Screen; 2012 Sep; 19(3):154-6. PubMed ID: 23060474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
    Hüsing A; Kaaks R
    Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Prediction Models for Identifying Malignancy in Pulmonary Nodules Detected via Low-Dose Computed Tomography.
    González Maldonado S; Delorme S; Hüsing A; Motsch E; Kauczor HU; Heussel CP; Kaaks R
    JAMA Netw Open; 2020 Feb; 3(2):e1921221. PubMed ID: 32058555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    Fu M; Travier N; Martín-Sánchez JC; Martínez-Sánchez JM; Vidal C; Garcia M;
    PLoS One; 2018; 13(4):e0195441. PubMed ID: 29621354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    ; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
    JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External validation and recalibration of the Brock model to predict probability of cancer in pulmonary nodules using NLST data.
    Winter A; Aberle DR; Hsu W
    Thorax; 2019 Jun; 74(6):551-563. PubMed ID: 30898897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Robbins HA; Alcala K; Swerdlow AJ; Schoemaker MJ; Wareham N; Travis RC; Crosbie PAJ; Callister M; Baldwin DR; Landy R; Johansson M
    Br J Cancer; 2021 Jun; 124(12):2026-2034. PubMed ID: 33846525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
    J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.
    Reich JM; Kim JS
    AJR Am J Roentgenol; 2015 Aug; 205(2):278-9. PubMed ID: 26204275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.